Cargando…

Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial

BACKGROUND: In China, cervical cancer is the fifth most commonly diagnosed cancer, and the outcomes for patients with advanced or recurrent disease are poor. Apatinib, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR-2), is an orally bioavailable agent, which has show...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jian-Guo, Zhou, Nan-Jing, Zhang, Qiong, Feng, Yao-yao, Zhou, Hang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142681/
https://www.ncbi.nlm.nih.gov/pubmed/30223869
http://dx.doi.org/10.1186/s13063-018-2858-2